ClinicalTrials.gg
RecruitingNCT07669558Updated Aug 3, 2026

Electrical Impedance Tomography-Guided Identification of the Optimal Lateral Position in Postoperative ARDS

An interventional study of Positioning Intervention in Acute Respiratory Distress Syndrome (ARDS) and Postoperative, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.

Planned enrollment
70th of 81
22 · median 100
Started
2026
with 13 others
No phase
52 of 146
21 open now
Primary completion
2026-10
later than 24 of 54 live
Registered
139th of 146
by date
Lead sponsor
4 of 146
Ruijin Hospital

Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 70th largest by planned enrollment of the 81 interventional ones that give a count, is one of 14 that started in 2026, is one of 52 with no phase, reaches primary completion later than 24 of the 54 other live ones, and was the 139th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Respiratory Distress Syndrome with a site in China, or all of them as a file.
02

Study summary

This prospective, randomized crossover physiological study evaluates the effects of lateral positioning (left lateral position and right lateral position) versus the supine position on ventilation-perfusion (V/Q) matching in adult postoperative abdominal surgery participants with acute respiratory distress syndrome (ARDS). Bedside electrical impedance tomography (EIT) will be used to quantify regional ventilation and perfusion (perfusion derived from an intravenous tracer bolus administered during a brief breath-hold) and to calculate global "normal V/Q" (normal V/Q, %). Oxygenation, respiratory mechanics (when applicable), and hemodynamics will be recorded concurrently. Feasibility and safety of the positioning protocol will also be assessed.

Read the detailed description

Postoperative abdominal surgery patients commonly develop atelectasis, diaphragmatic dysfunction, and heterogeneous ventilation. When complicated by ARDS, ventilation-perfusion mismatch may worsen oxygenation and ventilatory efficiency. Prone positioning may be limited in this population because of abdominal incisions, drains, and intra-abdominal pressure concerns. Lateral positioning is frequently used in critical care and may improve V/Q coupling by changing gravitational gradients, chest wall mechanics, and pulmonary blood flow distribution; however, quantitative bedside evidence comparing left and right lateral positions is limited.

EIT is a radiation-free bedside functional imaging technique that can continuously monitor regional ventilation. In combination with a brief breath-hold and an intravenous tracer bolus, EIT can derive perfusion-related signals, enabling bedside quantification of V/Q matching.

In this randomized crossover study, each participant undergoes three body positions-supine position, left lateral position, and right lateral position-in a randomized order. The sequence (including whether left lateral or right lateral is performed first) is determined by random-number-based randomization. Each position stage lasts 60 minutes. After entering each position, participants are stabilized for 45 minutes before EIT measurements. EIT ventilation recording is obtained after stabilization, followed by an EIT perfusion assessment performed during a breath-hold of at least 8 seconds (actual breath-hold time recorded). During the breath-hold, a rapid intravenous tracer bolus is administered: 10 mL of 10% sodium chloride solution or 10 mL of 5% sodium bicarbonate solution, injected over 2-3 seconds via a central or peripheral venous line. Between position stages, participants return to the supine position for a 45-minute washout period. The primary endpoint is the difference in global normal V/Q (%) among the three positions. Secondary endpoints include other EIT-derived V/Q indices, oxygenation indices, respiratory mechanics, hemodynamic changes, and feasibility/safety outcomes. The primary statistical analysis required a minimum of 22 evaluable participants. Recruitment was planned to achieve at least this number to account for potential dropout. Recruitment would be terminated once sufficient evaluable subjects were obtained.

03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)
  • Postoperative

Keywords

  • acute respiratory distress syndrome (ARDS)
  • electrical impedance tomography (EIT
  • Lateral position
  • ventilation-perfusion
  • postoperative abdominal surgery
  • crossover study
  • supine position
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Postoperative abdominal surgery patients admitted to the ICU with ARDS (Berlin definition)
  • Considered able to tolerate protocolized position changes by the treating team
  • EIT belt placement and protocol procedures feasible
  • obtained from the patient or legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • to lateral positioning (e.g., unstable spine, uncontrolled bleeding, open abdomen, high-risk surgical wound condition)
  • Severe hemodynamic instability or other conditions making participation unsafe
  • High risk of airway/vascular line/drain dislodgement not manageable
  • Pregnancy
  • Refusal of
  • Any other condition deemed inappropriate by investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Arm 1: Supine Position

    Supine position with protocolized stabilization and EIT ventilation/perfusion measurements.

    Behavioral: Positioning Intervention

  • Experimental
    Arm 2: Left Lateral Position

    Left lateral position with protocolized stabilization and EIT ventilation/perfusion measurements.

    Behavioral: Positioning Intervention

  • Experimental
    Right Lateral Position

    Right lateral position with protocolized stabilization and EIT ventilation/perfusion measurements.

    Behavioral: Positioning Intervention

Interventions

  • BehavioralPositioning Intervention

    Using a randomized crossover design, all subjects undergo three body position stages in random order. Each position (supine, left lateral, right lateral) is maintained for 60 minutes. Vital signs are stabilized per protocol, followed by EIT assessment of ventilation-perfusion matching. 1. Position stage duration: 60 minutes. 2. Stabilization period before measurement: 45 minutes after position change. 3. Washout: 45-minute supine washout period between position stages. 4. EIT ventilation measurement: after stabilization in each position. 5. EIT perfusion measurement: during breath-hold ≥8 seconds (actual breath-hold time recorded. 6. Tracer bolus: 10 mL of 10% sodium chloride solution OR 10 mL of 5% sodium bicarbonate solution, injected over 2-3 seconds via central or peripheral venous line.

06

What researchers measure

Primary outcomes

  1. Global normal V/Q (%) derived from electrical impedance tomography (EIT)

    The percentage of lung pixels categorized as "normal ventilation-perfusion (V/Q)" according to pre-defined ventilation and perfusion signals acquired via EIT.

    Time frame: Post-stabilization in each body position (supine, left lateral, right lateral); assessments performed once per 60-minute positional stage, with comparative data reported for each position time point.

Secondary outcomes

  1. EIT-derived V/Q mismatch components (shunt-like lung pixel percentage, dead-space-like lung pixel percentage).

    Quantitative ventilation-perfusion mismatch metrics calculated from electrical impedance tomography (EIT) ventilation and perfusion signals, unit: %. Shunt-like %: Proportion of lung pixels with high perfusion but negligible ventilation Dead-space-like %: Proportion of lung pixels with robust ventilation but minimal perfusion These two indicators quantify the severity of pulmonary gas exchange disturbance under different body positions.

    Time frame: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (left lateral, right lateral); all V/Q mismatch data will be reported separately per positional time point for inter-position comparison.

  2. EIT-derived regional ventilation distribution indices

    A composite set of regional ventilation distribution parameters calculated from EIT signals, including center of ventilation (CoVX, CoVY), dorsal ventilation ratio (DVR), global inhomogeneity index (GI), ventral/dorsal impedance ratio, and ventilation fraction of four predefined ventrodorsal lung regions (ventral, mid-ventral, mid-dorsal, dorsal, expressed as %), used to evaluate regional ventilation uniformity and spatial distribution.

    Time frame: Single assessment time point after hemodynamic and respiratory stabilization within each 60-minute positional stage (left lateral, right lateral); comparative data of all indices will be reported separately for each positional assessment time point.

  3. EIT-derived regional perfusion distribution indices

    Quantitative perfusion parameters calculated from electrical impedance tomography (EIT) perfusion signals, including perfusion center coordinates (CoPX, CoPY), dorsal perfusion ratio (DPR), global perfusion inhomogeneity index, regional perfusion delay, and perfusion percentage of four predefined ventrodorsal lung regions (ventral, mid-ventral, mid-dorsal, dorsal, unit: %). These indices quantitatively characterize spatial perfusion redistribution, perfusion homogeneity, and temporal perfusion lag in supine, left lateral and right lateral positions.

    Time frame: Single perfusion assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (left lateral, right lateral); all perfusion index data will be reported separately for each positional assessment time point.

  4. Oxygenation index (PaO₂/FiO₂ ratio if arterial blood gas sampling is feasible; SpO₂/FiO₂ ratio as an alternative surrogate index).

    Oxygenation index is calculated to reflect systemic oxygenation status. PaO₂/FiO₂ ratio (unit: mmHg) will be prioritized when arterial blood gas data are available; if arterial blood gas cannot be obtained, SpO₂/FiO₂ ratio will be adopted as the substitute parameter.

    Time frame: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral); oxygenation index values will be reported separately for each positional assessment time point.

  5. Ventilator-related pressure parameters (plateau pressure, driving pressure).

    Static respiratory pressure indicators automatically recorded by mechanical ventilator, only collected from participants receiving invasive mechanical ventilation. * Plateau pressure: Static airway plateau pressure, unit: cmH₂O * Driving pressure: Calculated as plateau pressure minus PEEP, unit: cmH₂O These two pressure metrics reflect alveolar mechanical load under controlled ventilation.

    Time frame: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral); all pressure values will be reported separately for each positional assessment time point.

  6. Respiratory system compliance (ventilator-derived parameter).

    A comprehensive respiratory mechanics index calculated as tidal volume divided by driving pressure, unit: mL/cmH₂O. Measurement is limited to invasively ventilated participants to evaluate the overall distensibility of lungs and chest wall.

    Time frame: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral; all compliance values will be reported separately for each positional assessment time point.

  7. Circulatory monitoring parameters (heart rate, mean arterial pressure, vasopressor use if available).

    Continuous hemodynamic readings collected via bedside invasive monitor for circulatory assessment. * Heart rate: unit: beats per minute (bpm) * Mean arterial pressure (MAP): unit: mmHg These two parameters reflect systemic circulatory stability during positional adjustment and EIT perfusion measurement. * Binary categorical indicator for vasopressor administration status and continuous dosage recording of vasopressors; administration status (yes/no) and dosage (μg/kg/min) to evaluate circulatory support intensity.

    Time frame: Two predefined assessment time points within each 60-minute positional stage (supine, left lateral, right lateral): 1) after full respiratory and hemodynamic stabilization; 2) around breath-hold and contrast bolus injection for perfusion acquisition.

  8. Proportion of participants completing all randomized 60-minute positional stages and inter-position washout periods.

    Binary participant-level endpoint (unit: proportion \[%\]) calculated as the number of participants who fully finished all three predefined body position stages and corresponding washout intervals divided by total enrolled participants. Used to assess overall study procedural feasibility.

    Time frame: Through study positional phase completion (from initiation of the first positional stage to the end of the final washout period following the last positional assessment); completion status data will be summarized across all participants.

  9. Number of participants with successful acquisition of analyzable EIT imaging datasets.

    Count-based feasibility metric (unit: number of participants). Defined as participants with complete, artifact-free EIT ventilation and perfusion images eligible for post-hoc quantitative regional lung function analysis.

    Time frame: Through study positional phase completion (from initiation of the first positional stage to the end of the final washout period following the last positional assessment); successful EIT acquisition counts will be aggregated for all enrolled subjects.

  10. Proportion of participants capable of maintaining breath-hold for at least 8 seconds during EIT perfusion imaging.

    Proportional feasibility endpoint (unit: proportion \[%\]). Calculated as participants who sustained ≥8-second breath-hold during contrast bolus perfusion scans divided by all participants undergoing EIT perfusion measurement.

    Time frame: Through positional phase completion (from first positional stage start to final post-position washout end); breath-hold compliance proportions summarized across all perfusion assessment time points.

  11. Number of participants with any procedure-related adverse event (desaturation, hypotension, arrhythmia, accidental tube/line/drain displacement).

    Safety count endpoint (unit: number of participants). Captures all acute adverse events directly associated with positional changes and EIT image acquisition during the study protocol.

    Time frame: Through positional phase completion (from first positional stage start to final post-position washout end); all adverse events captured and tallied during positional testing.

  12. Number of participants with early study termination secondary to positional intolerance.

    Tolerability safety metric (unit: number of participants). Records participants withdrawn prematurely from positional testing due to respiratory, hemodynamic or clinical intolerance to supine, left lateral or right lateral positioning.

    Time frame: Through positional phase completion (from first positional stage start to final post-position washout end); all early termination events documented and counted for pooled safety analysis.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 4 months is below that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 25, 2026
StartActual
Jun 28, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07669558
Lead sponsor
Ruijin Hospital
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jun 28, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Aug 3, 2026

Study contacts

Rui Zhang
Contact
ccmzhangrui@foxmail.com
+86 18801119381

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion